GH Research (GHRS)
NASDAQ: GHRS
· Real-Time Price · USD
13.10
-0.24 (-1.80%)
At close: Oct 03, 2025, 3:59 PM
13.09
-0.08%
After-hours: Oct 03, 2025, 04:49 PM EDT
-1.80% (1D)
| Bid | 11.89 |
| Market Cap | 812.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.02M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -18.99 |
| Forward PE | -8.04 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 14.7 |
| Volume | 522,158 |
| Avg. Volume (20D) | 296,441 |
| Open | 13.38 |
| Previous Close | 13.34 |
| Day's Range | 12.84 - 13.61 |
| 52-Week Range | 6.00 - 20.50 |
| Beta | 0.98 |
| Ex-Dividend Date | n/a |
About GHRS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GHRS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GHRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+0.76%
Shares of psychedelic companies are trading higher...
Unlock content with
Pro Subscription
2 months ago
+10.98%
Shares of psychedelic companies are trading higher following a report suggesting California Governor Newsom said he is "all in" on expanding access to psychedelics for therapeutic use.
2 months ago · proactiveinvestors.com
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidateatai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and es...
2 months ago · proactiveinvestors.co.uk
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and es...
